Associated Papers
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.
Shenoy PV et al.
Cancer Metastasis Reviews, 2025
Retrospective Evaluation of the Impact of SLCO1B1 Variation on Statin Effectiveness.
Ahmed Feldman M et al.
Journal of Personalized Medicine, 2025
Phenotype-Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism.
Böhm R et al.
Clinical Pharmacology and Therapeutics, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E et al.
Clinical Biochemistry, 2024
Interrogating Pharmacogenetics Using Next-Generation Sequencing.
Ji Y et al.
The Journal of Applied Laboratory Medicine, 2024
CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Lactic acidosis after allogeneic haematopoietic stem cell transplantation potentially related to letermovir.
Manczak B et al.
British Journal of Clinical Pharmacology, 2023
Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis.
Zhang Q et al.
Annals of Translational Medicine, 2022
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.
Dagli-Hernandez C et al.
Pharmacological Reports : Pr, 2022
Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis.
Lee DH et al.
Pharmaceutics, 2022
Pharmacogenetics of Praziquantel Metabolism: Evaluating the Cytochrome P450 Genes of Zimbabwean Patients During a Schistosomiasis Treatment.
Zdesenko G et al.
Frontiers in Genetics, 2022
Corrigendum: Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.
Keegan NP et al.
Frontiers in Genetics, 2022
Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report.
Stäuble CK et al.
International Journal of Molecular Sciences, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.
Keegan NP et al.
Frontiers in Genetics, 2021
Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM et al.
International Journal of Molecular Sciences, 2020
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Whole-exome sequencing identifies common and rare variant metabolic QTLs in a Middle Eastern population.
Yousri NA et al.
Nature Communications, 2018
Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant.
Almeida-Paulo GN et al.
The Pharmacogenomics Journal, 2018
Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK et al.
Therapeutic Drug Monitoring, 2017
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.
Hole K et al.
European Journal of Clinical Pharmacology, 2017
Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.
Tsamandouras N et al.
Pharmacogenetics and Genomics, 2017
Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.
Lesche D et al.
Clinical Transplantation, 2015
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I et al.
European Journal of Clinical Pharmacology, 2014
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR et al.
Cancer Chemotherapy and Pharmacology, 2013
Intronic polymorphisms of cytochromes P450.
Ingelman-Sundberg M et al.
Human Genomics, 2010
CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA et al.
Bmc Medical Genetics, 2005
Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.
Fukushima-Uesaka H et al.
Human Mutation, 2004